US Hereditary Angioedema Therapeutics Market

ID: MRFR/HC/15214-HCR

100 Pages

Garvit Vyas

September 2025

US Hereditary Angioedema Therapeutics Market Research Report By Type (Type I, Type II), By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others), By Treatment (Prophylaxis - Long-term Prophylaxis, Short-term Prophylaxis, On-demand), By Route of Administration (Intravenous, Subcutaneous, Oral) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Forecast to 2035

US Hereditary Angioedema Therapeutics Market Infographic

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Infographic

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

US Hereditary Angioedema Therapeutics Market Summary

The US Hereditary Angioedema Therapeutics market is poised for substantial growth, expanding from 1.65 USD billion in 2024 to 9.13 USD billion by 2035.

Key Market Trends & Highlights

US Hereditary Angioedema Therapeutics Key Trends and Highlights

The market is projected to grow at a compound annual growth rate of 16.83 percent from 2025 to 2035.
By 2035, the market value is expected to reach 9.13 USD billion, indicating a robust demand for therapeutics.
In 2024, the market is valued at 1.65 USD billion, reflecting the current investment in Hereditary Angioedema treatments.
Growing adoption of advanced therapies due to increasing awareness of Hereditary Angioedema is a major market driver.

US Hereditary Angioedema Therapeutics Market

CAGR

16.83%

Market Size & Forecast

2024 Market Size	1.65 (USD Billion)
2035 Market Size	9.13 (USD Billion)
CAGR (2025-2035)	16.83%

Major Players

AstraZeneca, Takeda Pharmaceutical, Regeneron Pharmaceuticals, CSL Behring, Shire, Emergent BioSolutions, Ridgeback Biotherapeutics, ChanRx, Amgen, Ionis Pharmaceuticals, Sanofi, Pharming Group, Intellia Therapeutics, Biocryst Pharmaceuticals, Vertex Pharmaceuticals

US Hereditary Angioedema Therapeutics Market Trends

The US Hereditary Angioedema (HAE) Therapeutics Market is currently witnessing notable trends driven by an increasing awareness of HAE and a rise in the diagnosis of this rare condition. Key market drivers include the availability of new and advanced treatment options, such as C1-esterase inhibitor therapies and bradykinin receptor antagonists, which have significantly improved patient outcomes.

Additionally, the emphasis on personalized medicine is helping tailor treatments to individual patient needs, enhancing overall therapeutic efficacy. Opportunities in this market are expanding as healthcare providers and pharmaceutical companies focus on developing innovative therapies exceeding current treatment capabilities.

The growing population of patients diagnosed with HAE in the US, which is estimated to be around 6,000 to 10,000 individuals, presents untapped potential for new drug development and therapies. There is also an increasing participation in clinical trials aimed at finding new treatments, which can provide patients with access to cutting-edge therapies while also advancing knowledge in this area.

Recent trends indicate that patient advocacy groups are playing a significant role in raising awareness and improving access to treatments. The collaboration between these groups and healthcare professionals is helping facilitate the understanding of HAE’s impact and promote timely diagnosis.

Furthermore, the US Food and Drug Administration's push for expedited drug approval processes is enabling quicker access to innovative therapies for patients, showcasing the commitment to enhancing care standards in the realm of hereditary angioedema treatment.

Market Segment Insights

Hereditary Angioedema Therapeutics Market Type Insights

The Type segment of the US Hereditary Angioedema Therapeutics Market is crucial in understanding the landscape of treatments available for this rare genetic disorder. The market is primarily categorized into Type I and Type II, each with unique characteristics and treatment requirements. Type I is characterized by a deficiency of the C1 esterase inhibitor, which leads to uncontrolled inflammation and swelling; hence, the demand for effective therapies has surged in recent years.

This type accounts for the majority of hereditary angioedema cases in the US, making it a significant focus for research and therapeutic developments. Patients often require on-demand treatment during acute attacks, which has spurred innovation in targeted therapies and the emergence of novel medications tailored specifically for this group.

On the other hand, Type II, although less common, is marked by the presence of dysfunctional C1 inhibitors, which can also lead to life-threatening episodes of swelling. The pathophysiology of Type II is similar to Type I, but the management strategies may differ, creating a distinct avenue for therapeutic options and challenges in care.

Both types present unique treatment paradigms and influence the US Hereditary Angioedema Therapeutics Market dynamics substantially. The increase in awareness and diagnosis of hereditary angioedema has improved patient outcomes, prompting more investment in Research and Development to explore potential biological therapies and genetic editing technologies.

Overall, the Type segment represents a vital component of the US Hereditary Angioedema Therapeutics Market, reflecting the complexity of the condition and the ongoing need for effective management strategies. The growing patient population and advancements in understanding the genetic basis of these disorders fuel demand for innovative solutions.

Hereditary Angioedema Therapeutics Market Drug Class Insights

The US Hereditary Angioedema Therapeutics Market within the Drug Class segment is witnessing significant attention from stakeholders, driven by the increasing prevalence of hereditary angioedema (HAE) and the growing demand for effective treatments. The segmentation includes various components such as C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others.

C1 Esterase Inhibitors are crucial as they directly address the deficiency in patients and have historically been a standard of care, significantly contributing to improving patient outcomes. Selective Bradykinin B2 Receptor Antagonists are gaining traction due to their innovative approach in managing angioedema episodes, providing an essential alternative to traditional therapies.

Kallikrein Inhibitors represent a newer class, showing promise in reducing the frequency and severity of HAE attacks, reflecting ongoing advancements in Research and Development within the industry. Others in this market category include a range of products that utilize different mechanisms of action to ensure effective management, appealing to a broader patient demographic.

Overall, the growth of the US Hereditary Angioedema Therapeutics Market segmentation reflects a trend toward more personalized and effective treatment options for patients suffering from this condition.

Hereditary Angioedema Therapeutics Market Treatment Insights

The Treatment segment of the US Hereditary Angioedema Therapeutics Market plays a crucial role in managing this rare genetic condition characterized by recurrent episodes of severe swelling. Within this segment, Prophylaxis is a vital approach used to prevent attacks, and it includes Long-term Prophylaxis, Short-term Prophylaxis, and On-demand therapies.

Long-term Prophylaxis is particularly significant as it helps to minimize the frequency and severity of attacks, which can greatly enhance the quality of life for patients. Short-term Prophylaxis is employed in specific situations, such as before surgical procedures or potential triggers, allowing patients to manage risks effectively.

On-demand therapies are designed for immediate relief during acute episodes, emphasizing the need for rapid action to alleviate symptoms. The dominance of these approaches is driven by the rising awareness of hereditary angioedema among healthcare professionals and patients alike, along with advancements in treatment modalities.

The US market continues to provide opportunities for innovation in treatment strategies, which is essential for meeting the needs of individuals affected by this complex condition. Overall, the segmentation within the Treatment segment underscores the diverse yet complementary strategies required to tackle hereditary angioedema effectively in the US.

Hereditary Angioedema Therapeutics Market Route of Administration Insights

The Route of Administration segment in the US Hereditary Angioedema Therapeutics Market is crucial for determining how therapies are delivered to patients effectively. Among the various options, Intravenous administration provides rapid therapeutic action and is essential for patients experiencing severe attacks, ensuring immediate relief.

Subcutaneous delivery is becoming increasingly popular due to its ease of use, allowing patients to self-administer medication at home, thereby enhancing treatment adherence and convenience. Oral administration also plays a significant role, particularly for long-term management, as it appeals to patients' preferences for non-invasive treatment methods.

The interplay between these routes addresses diverse patient needs and scenarios, driving innovation and fostering growth in the market. With a growing population affected by hereditary angioedema and advancements in drug formulations, the Route of Administration segment stands out as a key focus area for pharmaceutical companies aiming to expand their offerings and improve patient outcomes.

Furthermore, the increasing awareness of hereditary angioedema and ongoing Research and Development efforts are anticipated to bolster these routes, making safe and effective therapies more accessible to patients across the United States.

Hereditary Angioedema Therapeutics Market Distribution Channel Insights

The US Hereditary Angioedema Therapeutics Market is primarily segmented through various Distribution Channels, which play a crucial role in ensuring that patients have access to necessary treatments. Hospital Pharmacy is pivotal as it offers specialized medication management and immediate access to therapies for patients receiving treatment in clinical settings.

Retail Pharmacy has a substantial presence, providing convenience and accessibility for patients who prefer to obtain their medications within their local communities, making it a favored option for chronic condition management. Meanwhile, Online Pharmacy is gaining significant traction due to the increasing preference for telehealth services and the convenience of home delivery, especially post-pandemic.

The rise of digital health solutions has driven a notable shift towards online platforms, enabling patients to bypass traditional hurdles in accessing therapies. All these distribution channels are essential for meeting the diverse needs of patients, ultimately supporting the market growth by enhancing therapeutic reach and improving patient adherence to prescribed regimens in the US.

Get more detailed insights about US Hereditary Angioedema Therapeutics Market

Request Free Sample

Key Players and Competitive Insights

The US Hereditary Angioedema Therapeutics Market has become increasingly competitive as pharmaceutical companies strive to address the unmet medical needs of patients suffering from this rare and potentially life-threatening condition. The market is characterized by a range of therapeutic options, including C1-esterase inhibitor therapies, bradykinin receptor antagonists, and other innovative treatments aimed at reducing the frequency and severity of angioedema attacks.

The rise in awareness of hereditary angioedema, improved diagnostic techniques, and ongoing research and development efforts contribute to a dynamic landscape where companies are competing for market share and striving to deliver effective solutions that enhance patient outcomes. Regulatory advancements also play a critical role in shaping the competitive environment, facilitating the approval and commercialization of new therapeutics.

AstraZeneca holds a notable presence in the US Hereditary Angioedema Therapeutics Market, leveraging its strong research and development capabilities to address this niche therapeutic area. The company's approach is supported by its robust pipeline and commitment to innovation, which enables it to explore novel therapeutic modalities.

AstraZeneca's established distribution channels and collaborations with leading healthcare providers reinforce its market position. The company utilizes a patient-centered strategy, focusing on increasing awareness and providing comprehensive support to patients and healthcare professionals, thereby fostering brand loyalty and enhancing treatment adherence.

Moreover, AstraZeneca's investment in clinical trials demonstrates its dedication to ensuring the efficacy and safety of its therapies, further solidifying its reputation in the industry.

Takeda Pharmaceutical is another key player in the US Hereditary Angioedema Therapeutics Market, recognized for its comprehensive range of treatment options that cater to the needs of patients with this condition. The company's key products include C1-esterase inhibitors and bradykinin receptor antagonists, which have been developed to significantly reduce the frequency of angioedema attacks and improve quality of life.

Takeda's commitment to research and development is highlighted by its ongoing investment in clinical trials and its focus on innovation within the hereditary angioedema therapeutic domain. Furthermore, Takeda's strategic mergers and acquisitions have bolstered its portfolio, enabling the company to enhance its market presence and expand its reach within the US region.

By combining its operational strengths with a deep understanding of patient needs, Takeda aims to provide effective solutions while fortifying its position in the rapidly evolving landscape of hereditary angioedema therapeutics.

Key Companies in the US Hereditary Angioedema Therapeutics Market market include

Industry Developments

The US Hereditary Angioedema Therapeutics Market has seen significant developments recently. In June 2023, CSL Behring announced progress in its gene therapy development for hereditary angioedema, showcasing advancements in reducing treatment frequency for patients while enhancing efficacy.

Takeda Pharmaceutical reported elevated market performance due to the successful launch of its new therapies, which have gained traction among healthcare professionals and patients for their improved safety profiles. In terms of mergers and acquisitions, Emergent BioSolutions completed its acquisition of a small biotech firm focused on rare diseases, including hereditary angioedema, in July 2023.

Furthermore, Biocryst Pharmaceuticals achieved a market valuation growth following its innovative product launches; this has solidified its presence in the American market, contributing to an overall market expansion. Over the past two to three years, the market has also seen heightened competition and increased investment in Research and Development as companies such as Amgen and Regeneron Pharmaceuticals emphasize novel therapeutics aimed at improving patient outcomes.

Government support through funding for cutting-edge therapies has further stimulated market activity, promising a robust growth landscape for the industry moving forward.

Market Segmentation

Hereditary Angioedema Therapeutics Market Type Outlook

Type I
Type II

Hereditary Angioedema Therapeutics Market Treatment Outlook

Prophylaxis - Long-term Prophylaxis
Short-term Prophylaxis
On-demand

Hereditary Angioedema Therapeutics Market Drug Class Outlook

C1 Esterase Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Kallikrein Inhibitor
Others

Hereditary Angioedema Therapeutics Market Distribution Channel Outlook

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Hereditary Angioedema Therapeutics Market Route of Administration Outlook

Intravenous
Subcutaneous
Oral

Report Scope

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	1.43(USD Billion)
MARKET SIZE 2024	1.65(USD Billion)
MARKET SIZE 2035	9.13(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	16.827% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	AstraZeneca, Takeda Pharmaceutical, Regeneron Pharmaceuticals, CSL Behring, Shire, Emergent BioSolutions, Ridgeback Biotherapeutics, ChanRx, Amgen, Ionis Pharmaceuticals, Sanofi, Pharming Group, Intellia Therapeutics, Biocryst Pharmaceuticals, Vertex Pharmaceuticals
SEGMENTS COVERED	Type, Drug Class, Treatment, Route of Administration, Distribution Channel
KEY MARKET OPPORTUNITIES	Growing patient awareness programs, Advancements in gene therapy, Increased funding for research, Strategic partnerships and collaborations, Expanding telehealth services for management
KEY MARKET DYNAMICS	Increasing patient awareness, Rising treatment options, Strong pipeline developments, Regulatory support initiatives, High healthcare expenditure
COUNTRIES COVERED	US

FAQs

What is the expected market size of the US Hereditary Angioedema Therapeutics Market in 2024?

The US Hereditary Angioedema Therapeutics Market is expected to be valued at 1.65 billion USD in 2024.

What is the projected market size by 2035 for the US Hereditary Angioedema Therapeutics Market?

By 2035, the market is anticipated to reach a valuation of 9.13 billion USD.

What is the expected CAGR for the US Hereditary Angioedema Therapeutics Market from 2025 to 2035?

The market is projected to grow at a CAGR of 16.827% from 2025 to 2035.

Which segments are projected to lead the market in 2024?

Type I is expected to be valued at 0.99 billion USD and Type II at 0.66 billion USD in 2024.

What will be the market size for Type I and Type II by 2035?

Type I is projected to reach 5.15 billion USD, while Type II is expected to be valued at 3.98 billion USD by 2035.

Who are the key players in the US Hereditary Angioedema Therapeutics Market?

Major players include AstraZeneca, Takeda Pharmaceutical, Regeneron Pharmaceuticals, and CSL Behring among others.

What factors are driving growth in the US Hereditary Angioedema Therapeutics Market?

Increased awareness and better diagnostic options are key drivers of market growth.

What are the emerging trends in the US Hereditary Angioedema Therapeutics Market?

There is a trend towards novel therapies and personalized medicine in the market.

What challenges does the US Hereditary Angioedema Therapeutics Market face?

The market faces challenges such as high treatment costs and regulatory hurdles.

How does regionality impact the US Hereditary Angioedema Therapeutics Market?

The market dynamics can vary significantly across different regions due to varying healthcare access and awareness levels.

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Customer Stories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne Founder

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027